TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30736874

Group type: EXPERIMENTAL
Intervention: PAP adherence in the first 3 months (usage of the device for at least 4 hours per night on 70% of nights)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PAP adherence after the first 3 months
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Predictive value of adherence at 3 months for adherence at 1 year
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity of using adherence at 3 months to predict adherence at 1 year
Number of subjects: 42
Study: 30737049

Group type: EXPERIMENTAL
Intervention: Highest tertile of Dietary Inflammatory Index (DII)
Number of subjects: 1948

Group type: EXPERIMENTAL
Intervention: DII score
Number of subjects: 1948
Study: 30737137

Group type: EXPERIMENTAL
Intervention: Conservative management (ultrasound and clinical follow-up at intervals of 3 months, 6 months, and then every 12 months thereafter)
Number of subjects: 2587

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 2587
Study: 30737315

Group type: EXPERIMENTAL
Intervention: Intravenous meloxicam (5-60 mg)
Number of subjects: 1426

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1426

Group type: EXPERIMENTAL
Intervention: Intravenous meloxicam 5 mg
Number of subjects: 1426

Group type: EXPERIMENTAL
Intervention: Intravenous meloxicam 7.5 mg
Number of subjects: 1426

Group type: EXPERIMENTAL
Intervention: Intravenous meloxicam 15 mg
Number of subjects: 1426

Group type: EXPERIMENTAL
Intervention: Intravenous meloxicam
Number of subjects: 1426
Study: 30738245

Group type: EXPERIMENTAL
Intervention: Extracorporeal life support during cardiopulmonary resuscitation (ECPR)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Continued cardiopulmonary resuscitation (CCPR)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: ECPR
Number of subjects: 110
Study: 30738398

Group type: EXPERIMENTAL
Intervention: TiRobot-assisted group (RG)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Fluoroscopy-assisted group (FG)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 234
Study: 30738400

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the caudate nucleus body
Number of subjects: 6

Group type: COMPARATOR
Intervention: Electrical stimulation of the caudate head
Number of subjects: 6

Group type: COMPARATOR
Intervention: Functional connectivity comparison between caudate body and head
Number of subjects: 6
Study: 30738407

Group type: EXPERIMENTAL
Intervention: CoGNIT (Computerized General Neuropsychological INPH Test) administered preoperatively and at a postoperative follow-up 4 months after shunt surgery
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy elderly control volunteers
Number of subjects: 41
Study: 30738658

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (adjusted to average rates at 25-26 weeks, 89.2%) for resuscitated infants born at 23 weeks
Number of subjects: 4858

Group type: COMPARATOR
Intervention: Resuscitation without antenatal corticosteroids for infants born at 23 weeks
Number of subjects: 4858

Group type: COMPARATOR
Intervention: Discordant antenatal corticosteroid use and resuscitation for infants born at 22 weeks
Number of subjects: 4858

Group type: COMPARATOR
Intervention: Discordant antenatal corticosteroid use and resuscitation for infants born at 23 weeks
Number of subjects: 4858

Group type: COMPARATOR
Intervention: Discordant antenatal corticosteroid use and resuscitation for infants born at 24 weeks
Number of subjects: 4858

Group type: COMPARATOR
Intervention: Resuscitation for infants born at 22 weeks
Number of subjects: 4858
Study: 30738985

Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ERCP
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ERCP grade 2
Number of subjects: 37
Study: 30739055

Group type: EXPERIMENTAL
Intervention: Thoracic impedance (TI) monitoring
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: TI monitoring during intensified diuresis
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: TI monitoring for recurrent decompensations
Number of subjects: 497
Study: 30739258

Group type: EXPERIMENTAL
Intervention: New prognostic model for overall survival (OS) in second-line treatment.
Number of subjects: 1076

Group type: EXPERIMENTAL
Intervention: New independent prognostic factors identified: time from first to second-line treatment and tumor burden.
Number of subjects: 1076

Group type: EXPERIMENTAL
Intervention: Risk groups based on GRCC model.
Number of subjects: 1076
Study: 30739366

Group type: EXPERIMENTAL
Intervention: Ruzasvir 60 mg plus Uprifosbuvir 450 mg
Number of subjects: 160
Study: 30739368

Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin (OBV/PTV/r ± DSV ± RBV)
Number of subjects: 3808
Study: 30739387

Group type: EXPERIMENTAL
Intervention: C4M levels in females
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C4M levels in males
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C4M as a predictor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C4M and PRO-C4 levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender-specific profiles of C4M
Number of subjects: 0
Study: 30739576

Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel oral suspension (≤0.18 mg/kg/d)
Number of subjects: 0
Study: 30740545

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) treatments lasting 20-45 minutes twice weekly for 2-4 months during feeding therapy sessions by a trained occupational therapist (OT).
Number of subjects: 10
Study: 30740662

Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R (dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, rituximab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: End of treatment positron emission tomography scans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salvage immunochemotherapy and subsequent autologous stem cell transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel therapies targeting aberrant cellular signalling and immune evasion
Number of subjects: 0
Study: 30740673

Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Adiponectin and VAT adipocyte area
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: VAT adipocyte area
Number of subjects: 31
Study: 30741382

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide extended-release (TA-ER) injection
Number of subjects: 208
Study: 30741501

Group type: EXPERIMENTAL
Intervention: Lowest pressure pain thresholds (PPTs) in finger joints and remote locations
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Presence of temporal summation (TS)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds (PPTs) and presence of TS
Number of subjects: 282
Study: 30741694

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30741695

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30741812

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 300

Group type: COMPARATOR
Intervention: Vaginal progesterone (400 mg once a day)
Number of subjects: 300
Study: 30742211

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (n=1414)
Number of subjects: 3010

Group type: COMPARATOR
Intervention: Aspirin alone (n=1422)
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 3010

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 3010
Study: 30742483

Group type: EXPERIMENTAL
Intervention: Early functional mobilization in an orthosis
Number of subjects: 34
Study: 30742559

Group type: EXPERIMENTAL
Intervention: Hematopoietic stem-cell transplantation (HSCT) in first complete remission (CR1)
Number of subjects: 131

Group type: COMPARATOR
Intervention: No HSCT
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Patients with MRD of 0.01% or greater at the end of induction
Number of subjects: 131
Study: 30742566

Group type: EXPERIMENTAL
Intervention: Duvelisib 25 mg orally twice daily in 28-day cycles until progression, unacceptable toxicity, or death
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Duvelisib 25 mg orally twice daily
Number of subjects: 129
Study: 30742776

Group type: EXPERIMENTAL
Intervention: Diet and Art components
Number of subjects: 4681

Group type: EXPERIMENTAL
Intervention: Simultaneous practice of diet, art, and biofield therapy
Number of subjects: 4681

Group type: EXPERIMENTAL
Intervention: Increased frequency of components practiced
Number of subjects: 4681

Group type: EXPERIMENTAL
Intervention: Decreased frequency of components practiced
Number of subjects: 4681

Group type: EXPERIMENTAL
Intervention: Biofield therapy
Number of subjects: 4681
Study: 30742809

Group type: EXPERIMENTAL
Intervention: High-resolution CT (HRCT) scanning indexes
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Newly defined parameter AROIP
Number of subjects: 70
Study: 30742833

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 36
Study: 30743197

Group type: EXPERIMENTAL
Intervention: Microcephaly
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Major ultrasound abnormalities
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Combination of microcephaly and major ultrasound abnormalities
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Normal neurological examination, no major ultrasound findings, normal head size
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Microcephaly or major ultrasound abnormalities
Number of subjects: 132
Study: 30743210

Group type: EXPERIMENTAL
Intervention: No-Touch vein harvesting technique
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 2000
Study: 30744116

Group type: EXPERIMENTAL
Intervention: 6-min walking test (6MWT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Maximal oxygen uptake (VO₂max)
Number of subjects: 42
Study: 30744442

Group type: EXPERIMENTAL
Intervention: Minocycline (Tier 1: 800 mg loading dose followed by 200 mg BID for 7 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Minocycline (Tier 2: 800 mg loading dose followed by 400 mg BID for 7 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Minocycline (both tiers)
Number of subjects: 15
Study: 30744568

Group type: EXPERIMENTAL
Intervention: Isolation based on clinical judgement
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Highly contagious gastroenteritis (GE)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Risk factors for Norovirus
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Risk factors for C. difficile infections
Number of subjects: 227
Study: 30744587

Group type: EXPERIMENTAL
Intervention: Blood volume analysis (BVA) using radiolabeled albumin to measure intravascular blood volume (BV) at baseline and after 1-3 months.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Patients who had their prescribed estimated dry weight (EDW) changed after the initial BVA.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Patients who did not have their prescribed EDW changed after the initial BVA.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BVA measurements at the second measurement.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Change in weight.
Number of subjects: 10
Study: 30744591

Group type: EXPERIMENTAL
Intervention: Higher BMI (≥30)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Low muscle index
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Low muscle density
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Low subcutaneous fat index
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Low visceral fat index
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: High subcutaneous adipose tissue density
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: High visceral adipose tissue density
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: High visceral fat density
Number of subjects: 235
Study: 30744616

Group type: EXPERIMENTAL
Intervention: Early bronchoscopy (performed during active bleeding/≤48 h after hemoptysis stopped)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Delayed examination
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Early bronchoscopy
Number of subjects: 486
Study: 30744627

Group type: EXPERIMENTAL
Intervention: Quali-Palli-Patient questionnaire
Number of subjects: 214
Study: 30744680

Group type: EXPERIMENTAL
Intervention: Cord blood analysis
Number of subjects: 1019

Group type: EXPERIMENTAL
Intervention: Cord tissue analysis
Number of subjects: 1019

Group type: EXPERIMENTAL
Intervention: Comparison of both tissues
Number of subjects: 1019
Study: 30744681

Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity (3 sessions of 60 min each per week, 2 supervised and 1 unsupervised)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Best practice usual care
Number of subjects: 280
Study: 30745002

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 11308
Study: 30745090

Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin 2.0 mg/kg intravenously once every 3 weeks (recommended phase 2 dose)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin 2.0 mg/kg intravenously once every 3 weeks
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin
Number of subjects: 174
Study: 30745123

Group type: EXPERIMENTAL
Intervention: PSEN1 mutation (Ile416Thr)
Number of subjects: 93
Study: 30745256

Group type: EXPERIMENTAL
Intervention: Cobalt-chromium everolimus-eluting stents (CoCr-EES)
Number of subjects: 17068

Group type: EXPERIMENTAL
Intervention: Platinum-chromium EES (PtCr-EES)
Number of subjects: 17068

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stents (Re-ZES)
Number of subjects: 17068

Group type: EXPERIMENTAL
Intervention: Biomatrix biolimus-eluting stents (Bi-BES)
Number of subjects: 17068

Group type: EXPERIMENTAL
Intervention: Nobori BES (No-BES)
Number of subjects: 17068

Group type: EXPERIMENTAL
Intervention: Xience Prime cobalt-chromium EES (Pr-CoCr-EES)
Number of subjects: 17068

Group type: EXPERIMENTAL
Intervention: First-generation sirolimus-eluting stents (SES)
Number of subjects: 17068
Study: 30745365

Group type: EXPERIMENTAL
Intervention: Autologous lymphocyte infusion combined with peri-autoSCT immunotherapy with recombinant MAGE-A3 and adjuvant
Number of subjects: 13
Study: 30745399

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 22661
Study: 30746241

Group type: EXPERIMENTAL
Intervention: CBCT-guided bronchoscopy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CBCT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Radiation dose from CBCT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Number of subjects: 20
Study: 30746344

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid (EPA) 2 g/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30662958

Group type: EXPERIMENTAL
Intervention: Individual rewards
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed rewards
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no rewards)
Number of subjects: 0
Study: 30746608

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 110 mg BID (DE110)
Number of subjects: 4281

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg BID (DE150)
Number of subjects: 4281

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4281

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 4281

Group type: COMPARATOR
Intervention: Antiplatelets
Number of subjects: 4281

Group type: EXPERIMENTAL
Intervention: Switching from Warfarin to Dabigatran
Number of subjects: 4281
Study: 30747243

Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous IL-2 (125,000 IU/kg/day, maximum 9-10 doses over 2 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Non-myeloablative lymphodepleting chemotherapy, TIL, and low-dose IL-2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Biomarker assessment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TIL infusion product monitoring
Number of subjects: 12
Study: 30747273

Group type: EXPERIMENTAL
Intervention: Combination of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs), hydroxyapatite (HA) granules, bone morphogenetic protein-2 (BMP-2), and mechanical stabilization
Number of subjects: 6
Study: 30747313

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 250
Study: 30747311

Group type: EXPERIMENTAL
Intervention: Detoxified alcohol-dependent patients
Number of subjects: 39

Group type: COMPARATOR
Intervention: Matched healthy controls
Number of subjects: 39
Study: 30747374

Group type: EXPERIMENTAL
Intervention: Minimally invasive resections
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Overall morbidity
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Readmission
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Reoperation
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Post-operative length of stay (LOS)
Number of subjects: 1546
Study: 30747487

Group type: EXPERIMENTAL
Intervention: Endothelial microparticles (EMP) in SSc-PAH patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Endothelial microparticles (EMP) in SSc patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Endothelial microparticles (EMP) in limited SSc patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Microparticles (MP) from SSc patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Microparticles (MP) from healthy controls
Number of subjects: 30
Study: 30747550

Group type: EXPERIMENTAL
Intervention: Scalp Itch Numeric Rating Scale
Number of subjects: 0
Study: 30747719

Group type: EXPERIMENTAL
Intervention: Incentives for adherence to antidepressant medications in the first 6 weeks of treatment (Project 1: ADAPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normative pressure and social status to increase data collection among community mental health workers (Project 2: ASSISTS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participatory design for organizational-level implementation strategies (Project 3: MOTIVATE)
Number of subjects: 0
Study: 30753254

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Atenolol/Candesartan
Number of subjects: 236
Study: 30753274

Group type: EXPERIMENTAL
Intervention: Paclitaxel and trastuzumab
Number of subjects: 406
Study: 30753496

Group type: EXPERIMENTAL
Intervention: Preoperative B-type natriuretic peptide (BNP) measurement
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Postoperative BNP measurement on day 1 and day 2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 6-min walk test and Medical Research Council dyspnoea scale
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: BNP levels at all perioperative time points
Number of subjects: 27
Study: 30753549

Group type: EXPERIMENTAL
Intervention: Tryptophan intake ranging from 0.5 to 9.75 mg.kg-1.d-1
Number of subjects: 7

Group type: COMPARATOR
Intervention: Current recommended EAR and RDA for healthy growing children
Number of subjects: 7
Study: 30753611

Group type: EXPERIMENTAL
Intervention: IMA950/poly-ICLC vaccine
Number of subjects: 19
Study: 30753685

Group type: EXPERIMENTAL
Intervention: Dietary supplements (DS)
Number of subjects: 0
Study: 30753761

Group type: EXPERIMENTAL
Intervention: Cannabinoids
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Synthetic cannabinoids
Number of subjects: 251
Study: 30755071

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 2932

Group type: COMPARATOR
Intervention: No β-blockers
Number of subjects: 2932
Study: 30755109

Group type: EXPERIMENTAL
Intervention: Telephone-delivered, nurse-led symptom management intervention
Number of subjects: 25
Study: 30755362

Group type: EXPERIMENTAL
Intervention: VSR
Number of subjects: 146

Group type: COMPARATOR
Intervention: FWR
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Percutaneous repair at 1-2 weeks following AMI
Number of subjects: 146
Study: 30755445

Group type: EXPERIMENTAL
Intervention: AGuIX nanoparticles combined with WBRT (30 Gy, 10 fractions of 3 Gy)
Number of subjects: 15
Study: 30755498

Group type: EXPERIMENTAL
Intervention: Pressurised intraperitoneal aerosol chemotherapy (PIPAC)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Negative control group (benign PLF specimens and inflammatory ascites)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PIPAC treatment response
Number of subjects: 35
Study: 30755907

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (initial test dose)
Number of subjects: 1
Study: 30756297

Group type: EXPERIMENTAL
Intervention: 100% pasteurized watermelon juice (360 ml)
Number of subjects: 8
Study: 30756308

Group type: EXPERIMENTAL
Intervention: BI 853520 200 mg once daily (QD)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: BI 853520 200 mg QD
Number of subjects: 96
Study: 30756321

Group type: EXPERIMENTAL
Intervention: Self-reported habitual snoring (snorers group, n=787)
Number of subjects: 4495

Group type: COMPARATOR
Intervention: Nonsnoring (nonsnorers group, n=3708)
Number of subjects: 4495
Study: 30756337

Group type: EXPERIMENTAL
Intervention: Normal bimanual compression of a self-inflating resuscitation bag
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Maximal bimanual compression of a self-inflating resuscitation bag
Number of subjects: 35
Study: 30758276

Group type: EXPERIMENTAL
Intervention: High-priority stroke dispatch code
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Bystander caller
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Confusion
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Fall at onset
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Call recordings analysis
Number of subjects: 625
Study: 30758293

Group type: EXPERIMENTAL
Intervention: Behavior change technique-based smartphone game
Number of subjects: 36

Group type: COMPARATOR
Intervention: One-time lifestyle counseling
Number of subjects: 36